Strategies for Rapid Scale-up of Diverse asiRNA Duplexes

Time: 3:00 pm
day: Day Two


  • Our asiRNA portfolio is designed to treat ocular, dermatologic, alopecia and multiple liver diseases; diverse conjugation strategy poses unique chemistry-related challenges
  • Rapid product delivery is often required to meet tight timelines for first-in-human clinical studies while developing robust production processes. Significant issues were encountered during the synthesis of lipid and GalNAc-conjugated strands
  • Phase-appropriate strategies were implemented to address the challenges associated with each program